Cocrystal Pharma, Inc.
COCP
$1.31
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -37.17% | -24.74% | |||
| Gross Profit | 37.17% | 24.74% | |||
| SG&A Expenses | -33.72% | 57.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.94% | -7.45% | |||
| Operating Income | 35.94% | 7.45% | |||
| Income Before Tax | 33.87% | 7.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.87% | 7.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.87% | 7.56% | |||
| EBIT | 35.94% | 7.45% | |||
| EBITDA | 36.11% | 7.44% | |||
| EPS Basic | 33.88% | 7.56% | |||
| Normalized Basic EPS | 33.88% | 7.56% | |||
| EPS Diluted | 33.88% | 7.56% | |||
| Normalized Diluted EPS | 33.88% | 7.56% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||